Disorders in the immune system may result in disease in the body, including autoimmune diseases, inflammatory diseases and cancer. Immunodeficiency diseases occur when the immune system is less active than normal, which may result in recurring and life-threatening infections. Immunodeficiency can either be the result of a genetic disease, such as severe combined immunodeficiency, or be produced by pharmaceuticals or an infection, such as the acquired immune deficiency syndrome (AIDS) that is caused by the retrovirus HIV. In contrast, autoimmune diseases result from a hyperactive immune system attacking normal tissues as if they were foreign organisms. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus type 1, and lupus erythematosus. Immunology covers the study of all aspects of the immune system, having significant relevance to health and diseases.
The therapeutic goal for GVT® is preventive treatment of inflammatory complications arising from surgery of the abdominal organs. Any surgical intervention adversely impacts all links of the humoral immune protection system. Surgical treatment alters phagocytosis, cellular and humoral immunity. Such complications induce development of infectious, or septic, postoperative complications. Complex treatments including immunomodulatory anti-inflammatory therapies help protect the organism, improve surgical outcomes, and reduce the risk of post-operative deaths.
The target indication for GVT® includes use in treatment
of acute pancreatitis, acute peritonitis, chronic and acute
gastric and duodenal ulcers. GVT® is being used
for gynecological complications due to laparoscopic hysterectomy
surgeries, chronic endometritis, and urea-cervicitis.
Clinical Results
Clinical studies have provided evidence that GVT®:
Reduced surgical complications, decreased mortality rates, and reduced the number of hospital days in treatments of patients with acute peritonitis
Significantly accelerated healing of patients with duodenal ulcers
Reduced scarring of intestinal walls in patients with duodenal ulcers
Rapidly reduced abdominal and joint pain, reduced bleeding, reduced bowel movement in patients with ulcerative colitis and Crohn’s disease
Study Name
Location
Investigator/Author
A New Method of Correction of Immune Disorders in Patients with Acute Pancreatitis (2007)
Krasnoyarsk State Medical Academy, Dept of General Surgery, Professor S. Vinnik, Director
Vinnik YS, Cherdantsev DV, Pervova O, Miller SV, Markelov NM, Belokhvostikova TS
Galavit efficiency in prophylaxis and treatment of pyo-inflammatory complications at abdominal surgical pathology, Voenno-Meditsinskii Zhurnal, 2005 Jun; 326 (6): p 31-33 (PubMed ID: 16053046)
The Center of Modern Medicine, Ltd (Medicor)
Sukhorukov AL
Effectiveness of Galavit treatment of gastric and duodenal ulcer (2003)
IM Sechenov First Medical Institute, Moscow
AA Ovchinnikov
Commercial Potential for GVT®
In 2010, the global market for drugs for the treatment of immune disease was estimated to have been approximately $72.2 billion. The market size is forecast to grow at a compound annual growth rate (CAGR) of 2.6% to reach $82.2 billion by 2015.
The market size of immunomodulators in 2010 was estimated to be $62.8 billion, accounting for 86.9% of the overall market. The market for immunomodulators is expected to grow by a compound annual growth rate (CAGR) of 3.4% to reach $74.1 billion by 2015, accounting for 90.2% of the market.
The demand for symptom–treating drugs is declining as advancements in immunology and life sciences help to target the underlying causes of the diseases. The market size of symptom treating diseases is expected to decline at a compound annual growth rate (CAGR) of –3.1% from $9.4 billion in 2010 to $8.1 billion in 2015.
Source: BCC Research
Indications Immunology & Inflammation Clinical Studies Bach’s Monosodium Luminol products have been widely used in approved countries for many years in conjunction with surgical complications and diseases involving abdominal organs.For a brief summary click
here.
Select Monosodium Luminol Clinical Studies in Immunology and Inflammation
Using the immunomodulator Monosodium Luminol in the plan for the intergrated treatment of recurrent aphthous stomatitis
Efficiency of Monosodium Luminol in prevention and treatment of purulent inflammatory complicatons after abdominal surgical pathology
Monosodium Luminol in the treatment of uveitis with unclear and viral etiology
Integrated management of limited scleroderma
Immunocorrection using Monosodium Luminol with destructive pancreatitis
Experience of Monosodium Luminol in the post-operative period in the treatment of purulent-septic complications
Experience of Monosodium Luminol in gynecological patients with purulent inflammatory diseases of the pelvic organs
Immunomodulating therapy in a rehabilitation program in patients with chronic endometriosis
Indications Immunology Immunomodulator Bach’s Monosodium Luminol products have been
approved for use as anti-inflammatory and immune-modulating
treatments in the Russian Federation since 1997. For a brief summary click
here.
Immunomodulating and Anti-Inflammatory Properties of Monosodium Luminol
The Ministry of Health of Russian Referation authorized Monosodium Luminol on March 31, 1997 as an anti-inflammatory and immunomodulating medication for the treatment of inflammatory diseases of the gastrointestinal tract
It has a fast pharmacological action as a positive effect was expressed by the disappearance of intoxication symptoms and diarrhea within the first days of endotoxemia; therefore it can be used in cases of acute intestine infections
Under the influence of Monosodium Luminol, a faster normalization of intraleukocyte components level of leukocyte microbicide system is achieved which indicates the efficacy of a Monosodium Luminol application in cases of acute intestine infections
Monosodium Luminol proved to be well tolerable, effective, and safe in numerous clinical trials
Indications Immunology – Clinical Studies
Numerous Clinical Trials have been completed worldwide using Bach’s Monosodium Luminol products as therapies for many disease-states involving the immune system and inflammatory conditions.
Select Monosodium Luminol Clinical Studies in Immunology and Inflammation
Monosodium Luminol efficiency in the course of per oral intake and para-ulceral injections in cases of stomach and duodenum ulcer
Monosodium Luminol efficiency administered IM in complex therapy of duodenum ulcers
Monosodium Luminol application for treatment of nonspecific ulcerative colitis
Clinical and immunological efficiency of Monosodium Luminol application in complex postoperative therapy of patients with general form of acute peritonitis
Monosodium Luminol used in complex therapy of chronic recurrent furunculosis
Safety and efficacy of Monosodium Luminol in complex therapy of patients with chronic recurrent herpetic infection (HSV-2)
Monosodium Luminol inhalations in complex therapy
of a chronic bronchitis
Efficiency of Monosodium Luminol application in patients with miliary and infiltrative tuberculosis on a background of antituberculous therapy
